Momentum Builds for ALX Oncology and Delta Apparel
- October 03rd, 2023
- 638 views
Shares of ALX Oncology Holdings Inc. (Nasdaq: ALXO) surged by more than 20% in after-hours trading following the announcement that it will unveil interim Phase 2 ASPEN-06 clinical trial results of evorpacept, aimed at treating advanced HER2-positive gastric cancer, on Tuesday, October 3.
$ALXO was trading at $5.90, marking a substantial increase of $1.09 (+22.66%) during the extended session.
In unrelated news, Delta Apparel, Inc. (NYSE American: DLA) revealed that it has received an unsolicited offer for its Salt Life business unit. The company's Board of Directors has enlisted Baird as its financial advisor for this development. It's important to note that the timing, terms, or structure of any potential transaction, as well as the likelihood of a transaction occurring, remain uncertain.
In after-hours, $DLA was trading at $7.89, up $1.30 (+19.73%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
What Wall Street Expects From Keysight, Mercury Systems, and Amer Sports: Earnings Preview
August 15th, 2026FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies
August 13th, 2026August 12th, 2026
Member Login